Subscribe to RSS
DOI: 10.1055/s-2007-982043
© Georg Thieme Verlag KG Stuttgart · New York
Infektiologie und Tropenmedizin 2007
Infectiology and tropical medicine 2007Publication History
eingereicht: 24.5.2007
akzeptiert: 24.5.2007
Publication Date:
15 June 2007 (online)
Was ist neu?
-
Neue Erreger: Klebsiellen- und E-coli-Stämme
-
Reisediarrhoe: Antibiotika im Test
-
Neue Antibiotika: Daptomycin, Tigecyclin, Dalbavancin, Telavancin
-
Antimykotika: Micafungin, zyklische b-Aminosäuren
-
Tuberkulose: Problematische Resistenzen. Lymphozyten-Stimulations-Test
-
HIV und AIDS: Prävention stagniert. Therapeutische Innovationen
-
Impfungen: Neue Empfehlungen, neue Entwicklungen
-
Malaria tropica: Artesunate bei komplizierter Malaria. Chikungunya-Fieber
Literatur
- 1 Anonymus. Newer approaches to HIV prevention. Lancet. 2007; 369 615
- 2 Bailey R C, Moses S, Parker C B. et al . Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007; 369 643-656
- 3 Blumenthal R, Dimitrov D S. Targeting the Sticky Fingers of HIV-1. Cell. 2007; 129 243-345
- 4 Brooks J T, Ochieng J B, Kumar L. et al . Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997 - 2003. Clin Infect Dis. 2006; 43 393-401)
- 5 CDC. Pertussis-United States, 2001 - 2003. MMWR Morb Mortal Wkly Rep. 2005; 54 1283-1286
- 6 Chen A Y, Zervos M J, Vazquez J A. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007; 61 853-863
- 7 Chretien J P, Anyamba A, Bedno S A. et al . Drought-associated chikungunya emergence along coastal East Africa. Am J Trop Med Hyg. 2007; 76 405-407
- 8 Clotet B, Bellos N, Molina J M. et al . Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007; 369 1169-1178
- 9 Dewan P K, Grinsdale J, Kawamura L M. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis. 2007; 44 69-73
- 10 Friedman L N, Nash E R, Bryant J. et al . High rate of negative results of tuberculin and QuantiFERON tests among individuals with a history of positive skin test results. Infect Control Hosp Epidemiol. 2006; 27 436-441
- 11 Gray R H, Kigozi G. et al . Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007; 369 657-666
- 12 Greenwald J L, Burstein G R, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006; 8 125-131
- 13 Grinsztejn B, Nguyen B Y. et al . Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007; 369 1261-1269
- 14 Hampton T. Marburg vaccine shows promise: offers postexposure protection in monkeys. Jama. 2006; 295 2346
- 15 Harper D M. et al . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18l. Lancet. 2006; 367 1247-1255
- 16 Hasenoehrl A, Galic T. et al . In Vitro Activity and In Vivo Efficacy of Icofungipen (PLD-118), a Novel Oral Antifungal Agent, against the Pathogenic Yeast Candida albicans. Antimicrob Agents Chemother. 2006; 50 3011-3018
- 17 Hasin T, Davidovitch N, Cohen R. et al . Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. N Engl J Med. 2006; 355 148-155
- 18 Hicks C B, Cahn P, Cooper D A. et al . Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006; 368 466-475
- 19 Hill D R, Ford L, Lalloo D G. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis. 2006; 6 361-373
- 20 Hoffmann H, Loytved G, Bodmer T. Interferon-γ-Release-Assays in der Tuberkulosediagnostik. Internist (Berl). 2007; 48 497-506
- 21 Högenauer C, Hammer F H, Krejs G J, Reisinger E C. Mechanisms and Management of Antibiotic-Associated Diarrhea. Clin Infect Dis. 1998; 27 702-710
- 22 Högenauer C, Langner C, Beubler E. et al . Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med. 2006; 355 2418-2426
- 23 Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006; 145 317-325
- 24 Kabir S. Cholera vaccines. Lancet Infect Dis. 2007; 7 176-178
- 25 Klug S J, Hukelmann M, Hollwitz B. et al . Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol. 2007; 79 616-525
- 26 Kobashi Y, Obase Y. et al . Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis. 2006; 43 1540-1546
- 27 Krause R, Schwab E, Bachhiesl D, Wenisch C, Krejs G J, Reisinger E C. Role of Candida in Antibiotic-Associated Diarrhea. J Infect Dis. 2001; 184 1065-1069
- 28 MacArthur R D. Darunavir: promising initial results. Lancet. 2007; 369 1143-1144
- 29 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146 340-345
- 30 Munch J, Standker L, Adermann K. et al . Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide. Cell. 2007; 129 263-275
- 31 Nataro J P, Mai V, Johnson J. et al . Diarrheagenic Escherichia coli infection in Baltimore, Maryland, and New Haven, Connecticut. Clin Infect Dis. 2006; 43 402-407
- 32 Oxman M N, Levin M J, Johnson G R. et al . A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352 2271-2284
- 33 Pai M, Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?. Clin Infect Dis. 2007; 44 74-77
- 34 Raad I, Hanna H, Jiang Y. et al . Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant Staphylococcus Bacteremic Isolates Embedded in Biofilm. Antimicrob Agents Chemother. 2007; 51 1656-1660
-
35 SurvStat. 2007. (Accessed 30.04.2007, 2007, at http://www3.rki.de/SurvStat.)
- 36 Reisinger E C, Burchard G D. Neues in der Infektiologie und Tropenmedizin. Dtsch Med Wochenschr. 2006; 131 1474-1478
- 37 RKI . Zum Welttuberkulosetag 2007. Tuberkulose irgendwo heißt Tuberkulose überall!. Epidemiol Bul. 2007; 11 87-93
- 38 Rothberg M B, Virapongse A, Smith K J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007; 44 1280-1288
- 39 Schmiedeskamp M R, Kockler D R. Human papillomavirus vaccines. Ann Pharmacother. 2006; 40 1344-1352
- 40 Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother. 2006; 50 4217-4219
- 41 Sidley P. South Africa acts to curb spread of lethal strain of TB. Bmj. 2006; 333 825
- 42 Steiner T S, Samie A, Guerrant R L. Infectious diarrhea: new pathogens and new challenges in developed and developing areas. Clin Infect Dis. 2006; 43 408-410
- 43 STIKO . Empfehlung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur Pertussis-Schutzimpfung. Epidemiol Bull. 2006; 3 21-23
- 44 STIKO . Neuerungen in den aktuellen Empfehlungen der Ständigen Impfkommission (STIKO) am RKI vom Juli 2006. Epidemiol Bull. 2006; 32 271-276
- 45 STIKO . Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung. Epidemiol Bull. 2007; 12 97-103
- 46 Taylor D N, Bourgeois A L. et al . A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. Am J Trop Med Hyg. 2006; 74 1060-1066
- 47 Teo J W, Thayalan P, Beer D. et al . Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob Agents Chemother. 2006; 50 3665-3673
- 48 Tornesello M L. et al . Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer. 2007; 2 1
- 49 Treanor J J, Schiff G M. et al . Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. Jama. 2007; 297 1577-1582
- 50 Tribble D R, Sanders J W, Pang L W. et al . Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis. 2007; 44 338-346
- 51 UNAIDS .Report on the global AIDS epidemic 2006. Geneva: UNAIDS 2006
- 52 WHO .Guidelines for the treatment of severe malaria. (Accessed 2007 - 05 - 11, 2007, at www.who.int/malaria/docs/TreatmentGuidelines2006.pdf ) 2006
- 53 Xu Q A, Yu F, Fan M W. et al . Immunogenicity and persistence of a targeted anti-caries DNA vaccine. J Dent Res. 2006; 85 91591-91598
- 54 Xu Q A, Yu F, Fan M W. et al . Protective efficacy of a targeted anti-caries DNA plasmid against cariogenic bacteria infections. Vaccine. 2007; 25 1191-1195
- 55 Stryjewski M E, Chu V H, O’Riordan W D. et al . Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 Study. Antimicrob Agents Chemother. 2006; 50(3) 862-867
- 56 Kohli M, Ferko N, Martin A. et al . Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer. 2007; 96(1) 143-150
- 57 Dondorp A, Nosten F, Stepniewska K. et al . Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005; 366(9487) 717-725
Prof. Dr. med. Emil C. Reisinger
Abteilung für Tropenmedizin und Infektionskrankheiten, Universitätsklinik Rostock
Ernst Heydemann Str. 6
18057 Rostock
Phone: 0381/4947511
Fax: 0381/4947509
Email: emil.reisinger@medizin.uni-rostock.de